Pfizer Inc.'s push for health regulators to authorize a third dose of its COVID-19 shot is not yet backed by evidence, despite the fast-spreading delta variant, vaccine experts said.
Pfizer and German partner BioNTech SE said last week that they will ask U.S. and European regulators within weeks to authorize a booster dose due to an increased risk of infection after six months.
The companies did not share the data showing that risk, but said it would soon be made public. A meeting with federal health officials to discuss the matter was scheduled for Monday, Pfizer said.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.